Magenta raises $50m, inks partnership with Novartis for stem cell transplant drugs

Magenta Therapeutics said today that it closed a $50 million Series B round and licensed a clinical-stage program from Novartis (NYSE:NVS) to advance its stem cell transplantation platform. The company also inked a partnership deal with Be The Match BioTherapies.

Google’s venture arm, GV, led the financing round and was joined by existing investors, including Atlas Venture and Third Rock Ventures.

Get the full story at our sister site, Drug Delivery Business News.

The post Magenta raises $50m, inks partnership with Novartis for stem cell transplant drugs appeared first on MassDevice.

from MassDevice http://ift.tt/2oTYWTA